Monopar Therapeutics Files 8-K: Financials & Exhibits
Ticker: MNPR · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits
Related Tickers: MNPR
TL;DR
Monopar Therapeutics filed an 8-K with updated financials and exhibits.
AI Summary
On March 5, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosures related to the company's financial health and operations. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing provides an update on Monopar Therapeutics' financial statements and exhibits, which are crucial for investors to assess the company's financial health and operational status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no immediate indication of significant new risks or events.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- March 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing by Monopar Therapeutics?
The primary purpose of this 8-K filing is to report financial statements and exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is March 5, 2024.
In which state was Monopar Therapeutics Inc. incorporated?
Monopar Therapeutics Inc. was incorporated in Delaware.
What is the address of Monopar Therapeutics' principal executive offices?
The address of Monopar Therapeutics' principal executive offices is 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the telephone number for Monopar Therapeutics, including the area code?
The telephone number for Monopar Therapeutics is (847) 388-0349.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-03-05 07:00:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240304_8k.htm (8-K) — 25KB
- ex_634401.htm (EX-99.1) — 12KB
- a01.jpg (GRAPHIC) — 64KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-006538.txt ( ) — 271KB
- mnpr-20240305.xsd (EX-101.SCH) — 3KB
- mnpr-20240305_def.xml (EX-101.DEF) — 12KB
- mnpr-20240305_lab.xml (EX-101.LAB) — 16KB
- mnpr-20240305_pre.xml (EX-101.PRE) — 12KB
- mnpr20240304_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 5, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing positive preclinical imaging data of a therapeutic radioisotope bound to its proprietary uPAR (urokinase plasminogen activator receptor) targeting agent MNPR-101. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated March 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: March 5, 2024 By: /s/ Kim R. Tsuchimoto Name: Kim R. Tsuchimoto Title: Chief Financial Officer and Director